NICE recommends apixaban but rejects roflumilast

New recommendations from the national body have been released regarding Eliquis and Daxas.

Eliquis is recommended by NICE for prevention of venous thromboembolism following hip replacement surgery | SCIENCE PHOTO LIBRARY
Eliquis is recommended by NICE for prevention of venous thromboembolism following hip replacement surgery | SCIENCE PHOTO LIBRARY

Eliquis approved

The National Institute for Health and Care Excellence (NICE) has recommended that apixaban (Eliquis) be made available on the NHS for the prevention of venous thromboembolism in adults after elective hip or knee replacement surgery.

The recommended dosage of apixaban is 2.5mg twice daily. The initial dose should be taken 12–24 hours after surgery. Treatment should be continued for 32–38 days following hip surgery or for 10–14 days following knee surgery.

Daxas rejected    

NICE rejected the use of roflumilast (Daxas) for the management of severe chronic obstructive pulmonary disease (COPD). The PDE4 inhibitor is recommended only as part of a clinical study for adults with severe COPD associated with chronic bronchitis with a history of frequent exacerbations, as an add-on to bronchodilator treatment.  

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases